STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
Guidelines for the management of patients with rheumatoid arthritis (RA) envisage that its therapy should be intensified if it is insufficiently effective; at the same time, reduction of its intensity of treatment may be discussed when the set goal has been successfully achieved. The EULAR guideline...
Main Authors: | M. A. Kotovskaya, N. Yu. Nikishina, Yu. A. Olyunin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2018-03-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2506 |
Similar Items
-
RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE
by: E. L. Nasonov, et al.
Published: (2018-07-01) -
Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial
by: Shangwen Lei, et al.
Published: (2022-07-01) -
POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY
by: E. L. Luchikhina, et al.
Published: (2016-12-01) -
Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01) -
ADALIMUMAB DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING SUSTAINED REMISSION
by: N. V. Demidova, et al.
Published: (2018-07-01)